Sublocade (buprenorphine) is a brand-name extended-release injection that’s prescribed for opioid use disorder. Sublocade has interactions with alcohol, some other drugs, and certain supplements.

Sublocade (buprenorphine) and Suboxone (buprenorphine/naloxone) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat opioid use disorder (OUD).

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy. Data published in the Journal of Addition Medicine Given the naturalistic, ...

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...

Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and ...

Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe. Publications highlight the importance of overcoming access barriers to ...

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...